Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 598 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EconoPred Plus Clear all
Recruiting Phase 4 Interventional

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

NCT05867329
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1 Interventional

Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis

NCT00017628
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
cyclophosphamide, filgrastim, methylprednisolone, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Northwestern Memorial Hospital
Other
Eligibility
0 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 4:16 PM EDT
Completed No phase listed Observational

Early Short Course Corticosteroids in COVID-19

NCT04374071
View directory record Official record
Conditions
COVID, Pneumonia, Viral
Interventions
Methylprednisolone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 24, 2026, 4:16 PM EDT
Withdrawn Phase 2 Interventional

Alipogene Tiparvovec for the Treatment of LPLD Patients

NCT02904772
View directory record Official record
Conditions
LPL Deficiency
Interventions
alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 24, 2026, 4:16 PM EDT
Not listed Phase 2 Interventional

Trial of Steroids in Pediatric Acute Lung Injury/ARDS

NCT01274260
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury (ALI)
Interventions
methylprednisolone, Normal Saline (0.9%)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1 Interventional

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT03551782
View directory record Official record
Conditions
Castration-Resistant Prostatic Neoplasms
Interventions
Cetrelimab 480 mg, Apalutamide 240 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
San Francisco, California • Shreveport, Louisiana • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

NCT00048165
View directory record Official record
Conditions
Heart Transplantation
Interventions
Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 24, 2026, 4:16 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00562965
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 24, 2026, 4:16 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Evaluation of Methylprednisolone or Ibuprofen on Efficacy of Nerve Blocks With Symptomatic Irreversible Pulpitis

NCT04157036
View directory record Official record
Conditions
Irreversible Pulpitis
Interventions
Ibuprofen, Methylprednisolone
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

NCT00005898
View directory record Official record
Conditions
Fanconi's Anemia
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, fludarabine, methylprednisolone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years to 34 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 4:16 PM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 24, 2026, 4:16 PM EDT
Enrolling by invitation Phase 4 Interventional

Focal Cerebral Arteriopathy Steroid Trial

NCT06040255
View directory record Official record
Conditions
Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke
Interventions
methylprednisolone, prednisolone, prednisone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

NCT00968253
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic Leukemia
Interventions
Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

NCT02286622
View directory record Official record
Conditions
Renal Impairment
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 24, 2026, 4:16 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
55
States / cities
Phoenix, Arizona • Clovis, California • Duarte, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT01534195
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1 Interventional

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

NCT02614612
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02737332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 24, 2026, 4:16 PM EDT
Withdrawn Not applicable Interventional

Steroids Helping Albuterol Responders Exclusively

NCT00798616
View directory record Official record
Conditions
Bronchiolitis
Interventions
prednisolone or methylprednisolone, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Weeks to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Belimumab for Lupus Nephritis

NCT02260934
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 24, 2026, 4:16 PM EDT
Terminated Phase 2 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01005914
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, imatinib mesylate, methotrexate, methylprednisolone, pegaspargase, vincristine sulfate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

NCT01144143
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Infliximab, Placebo, Standard of Care: Methylprednisolone acetate
Drug
Lead sponsor
Herbert Lindsley, MD
Other
Eligibility
35 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 24, 2026, 4:16 PM EDT
Completed Phase 1 Interventional

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

NCT01020539
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
Interventions
Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin
Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Month to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 24, 2026, 4:16 PM EDT